- Home
- UMAC vs CKPT Comparison
UMAC vs CKPT Comparison
Compare UMAC & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UMAC
- CKPT
- Stock Information
- Founded
- UMAC 2019
- CKPT 2014
- Country
- UMAC United States
- CKPT United States
- Employees
- UMAC N/A
- CKPT N/A
- Industry
- UMAC
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- UMAC
- CKPT Health Care
- Exchange
- UMAC Nasdaq
- CKPT Nasdaq
- Market Cap
- UMAC 165.6M
- CKPT 151.9M
- IPO Year
- UMAC 2024
- CKPT 2017
- Fundamental
- Price
- UMAC $12.95
- CKPT $3.18
- Analyst Decision
- UMAC Strong Buy
- CKPT Strong Buy
- Analyst Count
- UMAC 2
- CKPT 2
- Target Price
- UMAC $11.00
- CKPT $13.50
- AVG Volume (30 Days)
- UMAC 3.4M
- CKPT 1.3M
- Earning Date
- UMAC 02-20-2025
- CKPT 11-12-2024
- Dividend Yield
- UMAC N/A
- CKPT N/A
- EPS Growth
- UMAC N/A
- CKPT N/A
- EPS
- UMAC N/A
- CKPT N/A
- Revenue
- UMAC $3,561,303.00
- CKPT $47,000.00
- Revenue This Year
- UMAC N/A
- CKPT N/A
- Revenue Next Year
- UMAC $66.18
- CKPT $172,016.02
- P/E Ratio
- UMAC N/A
- CKPT N/A
- Revenue Growth
- UMAC N/A
- CKPT N/A
- 52 Week Low
- UMAC $0.98
- CKPT $1.38
- 52 Week High
- UMAC $23.62
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- UMAC 50.74
- CKPT 42.32
- Support Level
- UMAC $12.27
- CKPT $3.07
- Resistance Level
- UMAC $13.97
- CKPT $3.42
- Average True Range (ATR)
- UMAC 2.29
- CKPT 0.21
- MACD
- UMAC -0.63
- CKPT -0.02
- Stochastic Oscillator
- UMAC 19.81
- CKPT 15.71
About UMAC Unusual Machines Inc. Common Stock
Unusual Machines Inc is a development stage technology company.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.